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Abstract  
Introduction: Vascular endothelium is a cellular monolayer that covers the internal lumen of all blood vessels, thus separating 
blood from the vessel wall and tissues. The study of the role of endothelium in the pathogenesis of cardiovascular diseases led to 
an understanding of the concept of it as a target for the prevention and treatment of these pathologies. 
Research tasks: The purpose of this study was preclinical study of the allergic effect of the drug KUD975, based on a phenolic 
compound, which is a selective inhibitor of arginase 2. 
Methods: Experiments on the allergic properties of the phenolic compound KUD975, which is a selective inhibitor of arginase II, 
were carried out on albino sexually mature guinea pigs weighing 300 ± 20 g. The preparation was administered intragastrically 
as a suspension in a 1% starch paste using a specially prepared atraumatic probe at 0, 1 ml of suspension per 10 g of body 
weight of animals. As a control, we used data obtained in animals with intragastric administration of the corresponding volume 
of placebo-1% starch paste. 
Results: In the course of the study of the allergic properties of KUD975, when the reaction of active cutaneous anaphylaxis was 
formulated, it was found that the studied preparation in two and eight times daily therapeutic dosages did not possess allergic 
properties 
In the course of the study of the allergic properties of KUD975 in the formulation of a delayed-type hypersensitivity reaction, it 
was found that the study drug in two and eight times daily therapeutic dosages had no allergenic properties. Erythema, or, 
especially, infiltration and the appearance of ulcers at the site of administration as a resolving dose of the drug, as well as in the 
control of reactivity, were not observed in any animal participating in the experiment. 
Conclusion: When investigating the allergenic properties of the phenolic compound KUD975, which is a selective inhibitor of 
arginase II in the reaction of active cutaneous anaphylaxis, it was found that the study preparation in two and eight times daily 
therapeutic dosages does not have allergic properties. In the reaction of active cutaneous anaphylaxis in guinea pigs, the allergic 
properties of KUD975 in two and eight times daily therapeutic dosages were not detected 
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INTRODUCTION:  
The vascular endothelium is a cellular monolayer that 
covers the internal lumen of all blood vessels, thus 
separating blood from the vessel wall and tissues. 
The study of the role of endothelium in the 
pathogenesis of cardiovascular diseases led to an 
understanding of the concept of it as a target for the 
prevention and treatment of these pathologies 
Using the concept of privileged structures and 
methods of computer modeling, project participants 
assume the presence of endothelioprotective activity 
in phenolic compounds containing directly bound 
heteroatomic and / or heterocyclic structural 
fragments. The design of molecular structures of 
these low-molecular compounds was carried out 
using modern medical-chemical approaches and 
assumes a high probability of advancing the 
compounds being developed to preclinical and 
clinical trials. 
The purpose of this study was preclinical study of the 
allergic effect of the drug KUD975, based on a 
phenolic compound, which is a selective inhibitor of 
arginase 2. 
The search for innovative molecules [1, 2] is an 
important task of pharmacology. In addition, their 
study should be carried out on pharmacological 
targets [3, 4], in vivo models [5, 6], pharmacokinetic 
parameters [7, 8] and clinical studies [9, 10]. 
 
MATERIALS AND METHODS: 
Experiments to study the allergenic properties of 
KUD975 were carried out on albino sexually mature 
guinea pigs with a mass of 300 ± 20 g [11, 12]. 
In the course of the study of allergic properties, the 
drug KUD975 was used in two and eight times daily 
therapeutic doses. The twice daily therapeutic dose of 
the study drug for guinea pigs was 5.3 mg / kg / day, 
eight times - 21.2 mg / kg / day. 
The drug was administered intragastrically as a 
suspension in a 1% starch paste using a specially 
prepared atraumatic probe at the rate of 0.1 ml of 
suspension per 10 g of body weight of the animals. 
As a control, we used data obtained in animals with 
intragastric administration of the corresponding 
volume of placebo-1% starch paste. 
The animals were kept 5 in the cage, the males 
separately from the females. For the maintenance of 
animals, a system of individually ventilated cells 
Tecniplast, Italy with temperature control function 
was used. The distribution of animals in groups was 
carried out after a 10-day period of quarantine in 
accordance with gender and body weight. 
Identification - applying individual labels to the body. 
Forage throughout the study was used granulated. 
The water in the fillets is filtered, disinfected with 
ultraviolet irradiation. Layer - sterilized by UV- 
 
irradiation sawdust. Photoperiod - 12 hours a night / 
12 hours a day with artificial daylight fluorescent 
lighting. 
During the research, the study of allergic properties 
of KUD975 was carried out by setting up two 
reactions: active cutaneous anaphylaxis and delayed 
type hypersensitivity. 
Reaction of active cutaneous anaphylaxis. [11, 13] 
The animals were divided into the following groups 
(10 in the group, 5 females and 5 males): I - control; 
II - KUD975 in a dose of 5.3 mg / kg / day; III - 
KUD975 in a dose of 21.2 mg / kg / day. 
Sensitization of guinea pigs with the test drug was 
carried out by intragastric administration for 30 days. 
The next day after the last administration, 
anaphylactogenic activity was evaluated in the 
reaction of active cutaneous anaphylaxis by 
intradermal (in the back region) administration of the 
resolving dose of the test preparation in a volume of 
0.05 ml, and 0.05 ml of a sterile isotonic solution 
sodium chloride. 
The resolving dose was selected by the experimental 
method in such a way that it does not cause irritant 
effect at the site of administration. 5 males and 5 
female albino guinea-pigs were used to determine the 
resolving dose. Each guinea pig was injected 
intradermally with 0.05 ml of an aqueous solution of 
KUD975, film-coated tablets, 10 mg in the following 
concentrations: 20%, 10%, 5%, 2%, 1%. Then, for 
three hours, the places of administration were 
observed to determine the possible local irritant 
effect. It was found that after intradermal 
administration of 20% and 10% of KUD975 
solutions, there were signs of local irritating effect, 
consisting of local reddening of the skin. 
Intracutaneous administration of 5%, 2%, and 1% of 
aqueous solutions of KUD975 in this volume did not 
lead to signs of local irritant effect. Thus, in further 
experiments, the maximum concentration of the drug 
was used, which did not have a local irritant effect 
with intradermal administration, 5%. 
After 20-25 minutes, animals under light anesthesia 
were injected intravenously with 0.5 ml of a 1% 
solution of blue Evans. Thirty minutes later, the 
animals were euthanized and a blue spot on the inside 
of the skin at the injection site was determined by 
means of a caliper. 
Hypersensitivity reaction of delayed type 
The animals were divided into the following groups 
(10 in the group, 5 females and 5 males): IV - 
control; V - KUD975 in a dose of 5.3 mg / kg / day; 
VI - KUD975 in a dose of 21.2 mg / kg / day. 
Sensitization of guinea pigs with the test drug was 
carried out by intragastric administration for 30 days. 
Anaphylactogenic activity was assessed in a delayed-
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type hypersensitivity reaction through 10 and 30 
injections by intradermal (in the back) administration 
of the resolving dose of the test preparation-5% 
aqueous solution of the preparation in a volume of 
0.05 ml, and 0, 05 ml of sterile isotonic sodium 
chloride solution. The reaction was assessed visually 
after 1 hour, 24 hours and 48 hours on the outer 
surface of the skin and expressed in points according 
to the SV scale. Suvorov: 
0 points - no visible reaction; 
1 point - pale pink erythema throughout the site or 
along its periphery; 
2 points - bright pink erythema throughout the site or 
its periphery; 
3 points - red erythema throughout the site; 
4 points - infiltration and swelling of the skin 
(thickening of the skin fold) with or without 
erythema; 
5 points - erythema, marked infiltration, focal 
ulcerations (necrosis), hemorrhages are possible, 
crust formation. 
 
RESULTS AND DISCUSSION: 
In the course of the study of the allergenic properties 
of the study drug KUD975, the reaction of active 
cutaneous anaphylaxis was found to show that the 
study preparation in two and eight times daily 
therapeutic dosages does not have allergic properties 
(Table 1). The results of the study are presented in 
Table 1. 
 
 
 
 
Table 1: Results of the study of the allergic properties of KUD975 preparation in the formulation of the 
reaction of active cutaneous anaphylaxis 
 
№  
Group / Ingredient / Spot size, mm 
Control 
KUD975 
2,65 mg/kg 
KUD975 
21,2 mg/kg 
resolving 
dose 
reactivity 
control 
resolving 
dose 
reactivity 
control 
resolving 
dose 
reactivity 
control 
1 3.3 2.5 3.1 3 3.1 2.7 
2 2.8 2.7 2.6 3.3 3.2 2.5 
3 2.8 3.4 3.1 3.3 2.6 2.9 
4 2.9 3.4 2.9 2.9 3.3 3.4 
5 3.5 3.3 2.7 2.5 3.5 3.1 
6 3.4 3.1 3.5 3.4 3.4 2.9 
7 3.5 2.6 3. 2.9 3.1 3.2 
8 2.8 2.8 3.4 2.7 3.2 3.4 
9 2.8 3.3 3.3 3 2.8 3.1 
10 3.5 2.8 3 2.8 2.9 3.3 
Mean, M±m 3.1±0.1 3.0±0.1 3.1±0.1 3.0±0.1 3.1±0.1 3.1±0.1 
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It was found that in the guinea pigs sensitized by the 
test preparation, the size of the spots of exudate 
formed at the points of administration of the 
resolving doses reached a diameter of 3.5 mm and, on 
average, did not statistically significantly exceed the 
size of the exudate spots at the control points and in 
the control animals. 
Thus, in the reaction of active cutaneous anaphylaxis 
in guinea pigs, the allergic properties of KUD975 
preparation in two and eight times daily therapeutic 
dosages were not revealed. 
In the course of the study of the allergenic properties 
of the KUD975 preparation in the formulation of a 
delayed-type hypersensitivity reaction, it was found 
that the study preparation in two and eight times daily 
therapeutic dosages had no allergic properties (Table 
2).  
 
 
Table 2: Record of reaction results hypersensitivity delayed type 
 
№ п/п 
Group / Input / Evaluation of response in points 
after 1/24/48 hours after administration 
Control 
KUD975 
2,65 mg/kg 
KUD975 
21,2 mg/kg 
resolving 
dose 
reactivity 
control 
resolving 
dose 
reactivity 
control 
resolving 
dose 
reactivity 
control 
Through 
10 
introducti
ons of the 
preparatio
n 
1 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
2 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
3 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
4 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
5 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
6 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
7 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
8 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
9 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
10 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
After 30 
introducti
ons of the 
preparatio
n 
1 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
2 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
3 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
4 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
5 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
6 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
7 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
8 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
9 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
10 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 
 
Erythema, or, especially, infiltration and the appearance of ulcers at the site of administration as a resolving dose of 
the drug, as well as in the control of reactivity, were not observed in any animal participating in the experiment. 
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CONCLUSION:  
Experiments to study the allergenic properties of 
KUD975 were carried out on albino sexually mature 
guinea pigs with a mass of 300 ± 20 g [11, 12]. In the 
course of the study of allergic properties, the drug 
KUD975 was used in two and eight times daily 
therapeutic doses. The twice daily therapeutic dose of 
the study drug for guinea pigs was 5.3 mg / kg / day, 
eight times - 21.2 mg / kg / day When investigating 
the allergenic properties of the phenolic compound 
KUD975, which is a selective inhibitor of arginase II 
in the reaction of active cutaneous anaphylaxis, it was 
found that the study preparation in two and eight 
times daily therapeutic dosages does not have allergic 
properties. In the reaction of active cutaneous 
anaphylaxis in guinea pigs, the allergic properties of 
KUD975 in two and eight times daily therapeutic 
dosages were not detected. 
Thus, in the delayed-type hypersensitivity reaction in 
guinea pigs, the allergic properties of KUD975 
preparation in two and eight times daily therapeutic 
dosages were also not revealed. 
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